Oxidative stress in autosomal dominant polycystic kidney disease: player and/or early predictor for disease progression?
- PMID: 30105413
- DOI: 10.1007/s00467-018-4004-5
Oxidative stress in autosomal dominant polycystic kidney disease: player and/or early predictor for disease progression?
Abstract
Autosomal dominant polycystic kidney disease (ADPKD), caused by mutations in PKD1 or PKD2 genes, is the most common hereditary renal disease. Renal manifestations of ADPKD are gradual cyst development and kidney enlargement ultimately leading to end-stage renal disease. ADPKD also causes extrarenal manifestations, including endothelial dysfunction and hypertension. Both of these complications are linked with reduced nitric oxide levels related to excessive oxidative stress (OS). OS, defined as disturbances in the prooxidant/antioxidant balance, is harmful to cells due to the excessive generation of highly reactive oxygen and nitrogen free radicals. Next to endothelial dysfunction and hypertension, there is cumulative evidence that OS occurs in the early stages of ADPKD. In the current review, we aim to summarize the cardiovascular complications and the relevance of OS in ADPKD and, more specifically, in the early stages of the disease. First, we will briefly introduce the link between ADPKD and the early cardiovascular complications including hypertension. Secondly, we will describe the potential role of OS in the early stages of ADPKD and its possible importance beyond the chronic kidney disease (CKD) effect. Finally, we will discuss some pharmacological agents capable of reducing reactive oxygen species and OS, which might represent potential treatment targets for ADPKD.
Keywords: ADPKD; Cardiovascular complications; Children; Early stages; Endothelial dysfunction; Oxidative stress; Young adults.
Similar articles
-
Hypoxia and Endothelial Dysfunction in Autosomal-Dominant Polycystic Kidney Disease.Semin Nephrol. 2019 Nov;39(6):599-612. doi: 10.1016/j.semnephrol.2019.10.009. Semin Nephrol. 2019. PMID: 31836042 Review.
-
[Cardiovascular risk in polycystic kidney disease].G Ital Cardiol (Rome). 2015 Sep;16(9):479-84. doi: 10.1714/1988.21520. G Ital Cardiol (Rome). 2015. PMID: 26418387 Italian.
-
Hypertension in children with autosomal dominant polycystic kidney disease (ADPKD).Curr Hypertens Rev. 2013 Feb;9(1):21-6. doi: 10.2174/1573402111309010004. Curr Hypertens Rev. 2013. PMID: 23971640 Review.
-
Cardiovascular complications in autosomal dominant polycystic kidney disease.Curr Hypertens Rev. 2013 Feb;9(1):2-11. doi: 10.2174/1573402111309010002. Curr Hypertens Rev. 2013. PMID: 23971638 Review.
-
Variable renal disease progression in autosomal dominant polycystic kidney disease: a role for nitric oxide?J Nephrol. 2003 May-Jun;16(3):449-52. J Nephrol. 2003. PMID: 12832751 Review.
Cited by
-
Predictors of progression in autosomal dominant and autosomal recessive polycystic kidney disease.Pediatr Nephrol. 2021 Sep;36(9):2639-2658. doi: 10.1007/s00467-020-04869-w. Epub 2021 Jan 21. Pediatr Nephrol. 2021. PMID: 33474686 Free PMC article. Review.
-
Autosomal Dominant Polycystic Kidney Disease: Is There a Role for Autophagy?Int J Mol Sci. 2023 Sep 28;24(19):14666. doi: 10.3390/ijms241914666. Int J Mol Sci. 2023. PMID: 37834113 Free PMC article. Review.
-
Vascular Dysfunction in Polycystic Kidney Disease: A Mini-Review.J Vasc Res. 2023;60(3):125-136. doi: 10.1159/000531647. Epub 2023 Aug 3. J Vasc Res. 2023. PMID: 37536302 Free PMC article. Review.
-
The Role of Oxidative Stress in Kidney Injury.Antioxidants (Basel). 2023 Sep 16;12(9):1772. doi: 10.3390/antiox12091772. Antioxidants (Basel). 2023. PMID: 37760075 Free PMC article. Review.
-
Suppression of Foxo3-Gatm by miR-132-3p Accelerates Cyst Formation by Up-Regulating ROS in Autosomal Dominant Polycystic Kidney Disease.Biomol Ther (Seoul). 2021 May 1;29(3):311-320. doi: 10.4062/biomolther.2020.197. Biomol Ther (Seoul). 2021. PMID: 33408288 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous